Share on StockTwits

Rexahn Pharmaceuticals (NYSE:RNN) Director Chang Ho Ahn unloaded 136,193 shares of the stock on the open market in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $0.99, for a total transaction of $134,831.07. Following the completion of the transaction, the director now directly owns 6,813,924 shares in the company, valued at approximately $6,745,785. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Rexahn Pharmaceuticals (NYSE:RNN) traded down 1.36% on Monday, hitting $0.9075. 1,216,957 shares of the company’s stock traded hands. Rexahn Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $1.85. The stock has a 50-day moving average of $0.89 and a 200-day moving average of $0.95. The company’s market cap is $161.5 million.

Rexahn Pharmaceuticals (NYSE:RNN) last announced its earnings results on Tuesday, March 25th. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.06) by $0.05. On average, analysts predict that Rexahn Pharmaceuticals will post $-0.15 earnings per share for the current fiscal year.

Separately, analysts at Brinson Patrick initiated coverage on shares of Rexahn Pharmaceuticals in a research note on Monday, March 24th. They set an “outperform” rating on the stock.

Rexahn Pharmaceuticals, Inc (NYSE:RNN) is a clinical stage biopharmaceutical company developing and seeking to deliver cures for cancer and disorders of the central nervous system (CNS) to patients worldwide.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.